Drugs / NDV-HXP-S-KP.2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07215520 | Nov 2025 → Aug 2026 overdue | COVID-19 | CastleVax Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDV-HXP-S-KP.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215520 ↗ |
| Modality | Vaccine | “Newcastle Disease Virus-based Mucosal Vaccine” NCT07215520 ↗ |
| Route | Intranasal | “Nasal Administration of NDV-HXP-S-KP.2” NCT07215520 ↗ |